Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

Next Previous
Trial Profile

A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandefitemcel (Primary)
  • Indications Traumatic brain injuries
  • Focus Therapeutic Use
  • Acronyms STEMTRA
  • Sponsors SanBio

    • Most Recent Events

    • 26 Apr 2022 Final Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 05 Apr 2022 Positive results from the one-year analysis published in the SanBio Media Release.
    • 24 Mar 2022 According to a SanBio media release, final analysis results of the STEMTRA study including data up to 48 weeks will be announced and presented by Dr. Peter McAllister at the 2022 Annual Meeting of the American Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top